Teaser 3 - The Missing Factor: Optimizing Patient Outcomes With Emerging NFRTs for Hemophilia

This activity is an independent, accredited continuing education documentary series featuring an individual with hemophilia talking about their experiences and challenges with hemophilia management. Experts then discuss their approaches to managing these challenges and how new and emerging therapies could improve the patient experience.
This activity features a series of 3 video episodes. Learners can receive a total of 1.25 credits for completing all 3 videos in the playlist and submitting the evaluation form at the end of the series.
This series of independent, accredited continuing education activities is designed for healthcare professionals (HCPs), including physicians, PAs, NPs, and nurses, who treat people with bleeding and clotting disorders, including pediatric, primary care, and hematology HCPs.
The aim of the program is to educate the intended audience on the burden of living with hemophilia and how new and emerging non-factor replacement therapies (NFRTs) could help overcome barriers to treatment. The series will cover the benefits and drawbacks of currently available treatments for hemophilia, and explore the potential of several types of NFRT—including anti-tissue factor pathway inhibitors, next-generation factor(F) VIII mimetics, antithrombin inhibitors, and serine protease inhibitors—to overcome some of the limitations with current therapy.
Learning Objectives
Upon completion of this activity, learners will be able to:
• Describe unmet needs and barriers to optimal treatment of people with
hemophilia A and B
• Discuss how available and emerging NFRTs have the potential to overcome existing barriers to treatment with clotting factor concentrates
• Analyze clinical data for emerging NFRTs, such as anti-TFPIs and next-generation FVIII mimetics, including efficacy and safety outcomes
• Discuss the potential role of emerging NFRTs in the treatment paradigm for hemophilia A and B, and associated monitoring requirements

Faculty
Guy Young, MD—Program Chair
Director, Hemostasis and Thrombosis Program,
Principal Investigator, Coagulation Research Laboratory,
Children’s Hospital Los Angeles
Professor of Pediatrics,
Keck School of Medicine of USC
Los Angeles, CA

Stacy Croteau, MD, MMS
Pediatric Hematologist, Boston Children’s Hospital
Medical Director, Boston Hemophilia Center
Assistant Professor of Pediatrics, Harvard Medical School
Boston, MA

Lisa Boggio, MD, MS
Assistant Professor, Department of Pediatrics,
Rush University Medical Director,
Rush Hemophilia and Thrombophilia Center
Chicago, IL

Faculty and Staff Disclosures and Mitigation of Relevant Financial Interests
It is the policy of IMNE to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals involved in planning (eg, faculty, CME/CE provider staff, and educational partner staff) are expected to disclose any relevant financial relationships with ineligible companies over the past 24 months. It is also required that faculty identify and reference off-label products or investigational uses of pharmaceutical agents and medical devices.
The following disclosures have been made:
Guy Young, MD
• Speakers bureau: BioMarin, CSL Behring, Hema Biologics, Sanofi, Spark
• Product royalty/licensing fees: Viatris
• Consultant: BioMarin, Centessa, CSL Behring, Genentech/Roche, Hema Biologics/LFB, Novo Nordisk, Octapharma, Pfizer, Sanofi Genzyme, Spark, Takeda
• Contracted research: Sanofi
• Dr Young discusses unlabeled/unapproved uses of non-factor replacement therapies for the treatment of hemophilia in this activity

Stacy Croteau, MD, MMS
• Consultant: BioMarin, Sanofi
• Contracted research: Sanofi, Spark Therapeutics
• Dr Croteau discusses unlabeled/unapproved uses of non-factor replacement therapies for the treatment of hemophilia in this activity

Lisa Boggio, MD, MS
• Speakers bureau: Recordati
• Consultant: Octapharma
• Contracted research: Sanofi, Regeneron, Bayer, Novo Nordisk, Octapharma, GBT,
Pharmacosmos, Principia

Staff Steve Weinman, MSc,
RN Director of Accreditation
ANCC Accredited Provider Program Director
Mr Weinman has nothing to disclose

Amy Groves, BS (With Honors)
Business Lead
Ms Groves has nothing to disclose
Claire Barnard, PhD
Editorial Team Leader
Dr Barnard has nothing to disclose

Tim Wale, BA
Associate Program Director
Mr Wale has nothing to disclose

CME Peer Reviewer
Martin Quan, MD
Dr Quan has nothing to disclose

Commercial Support Acknowledgment
This activity is supported by an educational grant from Novo Nordisk, Inc.